{"title":"基于嵌合抗原受体 T 细胞的癌症细胞疗法:简介和印度观点。","authors":"Reena J Rathod, Reghu K Sukumaran, Neelam Kedia, Jeevan Kumar, Reena Nair, Mammen Chandy, Lakshmikanth Gandikota, Vivek Sulekha Radhakrishnan","doi":"10.4103/ijc.ijc_433_21","DOIUrl":null,"url":null,"abstract":"<p><p>Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.</p>","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":" ","pages":"204-214"},"PeriodicalIF":0.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.\",\"authors\":\"Reena J Rathod, Reghu K Sukumaran, Neelam Kedia, Jeevan Kumar, Reena Nair, Mammen Chandy, Lakshmikanth Gandikota, Vivek Sulekha Radhakrishnan\",\"doi\":\"10.4103/ijc.ijc_433_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.</p>\",\"PeriodicalId\":13505,\"journal\":{\"name\":\"Indian journal of cancer\",\"volume\":\" \",\"pages\":\"204-214\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian journal of cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/ijc.ijc_433_21\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijc.ijc_433_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
摘要:利用自身免疫系统治疗癌症一直是癌症生物学和治疗学的一个活跃研究领域。细胞免疫疗法中的一个机会就是采用性细胞转移。最近,CAR-T疗法作为一种癌症治疗方法获得批准,开创了一种全新的癌症治疗模式,为复发/难治性癌症患者带来了一线希望。尽管临床结果令人鼓舞,但这种疗法仍处于早期阶段,由于其高昂的费用和物流方面的挑战,大多数患者仍无法接受。在印度,这些疗法尚不可用,而经济上的挑战和庞大的人口数量又进一步加剧了这一问题。在这篇综述中,我们将讨论 T 细胞免疫疗法的各个方面,特别关注 CAR-T 在印度的应用。我们探讨了 CAR-T 细胞疗法的基础科学、作用机制、生产、临床和商业方面,以及它在全球和印度的未来。
Chimeric Antigen Receptor T-cell based cellular therapies for cancer: An introduction and Indian perspective.
Using one's own immune system for curing cancer has been an active field of research in cancer biology and therapeutics. One such opportunity in cellular immunotherapy is adoptive cell transfers. With the recent approval of CAR-T therapy as a cancer treatment, a whole new paradigm of cancer treatment has opened-up, with a ray of hope for relapsed/refractory cancer patients. Despite promising clinical outcomes, the therapy is in its early phase and remains out of reach for most patients due to its high cost and logistic challenges. In India, these therapies are unavailable and further confounded by the economic challenges and a large population. In this review, we discuss various aspects of T-cell immunotherapies with a special focus on CAR-T in the Indian scenario. We touch upon the basic scientific aspects, mechanism of action, manufacturing, clinical aspects and commercial aspects of the CAR-Tcell therapies and its future worldwide and in India.
期刊介绍:
Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of ontological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India.